http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 21 Jul 2026 06:45:06 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Biogen+%28BIIB%29+PT+Raised+to+%24280+at+Guggenheim/26791859.html Guggenheim analyst Yatin Suneja raised the price target on Biogen (NASDAQ: BIIB) to $280.00 (from $260.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Biogen+%28BIIB%29+PT+Raised+to+%24280+at+Guggenheim/26791859.html Tue, 21 Jul 2026 06:45:06 -0400 BIIB http://www.streetinsider.com/Analyst+PT+Change/Biogen+%28BIIB%29+PT+Lowered+to+%24215+at+BofA+Securities/26791250.html <p>BofA Securities analyst Jason Zemansky lowered the price target on Biogen (NASDAQ: BIIB) to $215.00 (from $217.00) while maintaining a Neutral rating.</p><p>The analyst comments "Biogen’s 2Q results, while unlikely to generate the same headlines as last week’s diranersen Alzheimer’s presentation (see our final AAIC takes), might prove more capable of sustaining the recent positive shift in sentiment, with debate still centered on the long-term growth outlook. After proving surprisingly durable over the last few quarters, further indications of strength from the legacy portfolio, along with greater traction from new products, could reassure investors the business has a firmer floor, putting http://www.streetinsider.com/Analyst+PT+Change/Biogen+%28BIIB%29+PT+Lowered+to+%24215+at+BofA+Securities/26791250.html Tue, 21 Jul 2026 05:31:45 -0400 BIIB http://www.streetinsider.com/Analyst+Comments/Biogen+%28BIIB%29+PT+Lowered+to+%24215+at+BofA+Securities/26791250.html <p>BofA Securities analyst Jason Zemansky lowered the price target on Biogen (NASDAQ: BIIB) to $215.00 (from $217.00) while maintaining a Neutral rating.</p><p>The analyst comments "Biogen’s 2Q results, while unlikely to generate the same headlines as last week’s diranersen Alzheimer’s presentation (see our final AAIC takes), might prove more capable of sustaining the recent positive shift in sentiment, with debate still centered on the long-term growth outlook. After proving surprisingly durable over the last few quarters, further indications of strength from the legacy portfolio, along with greater traction from new products, could reassure investors the business has a firmer floor, putting http://www.streetinsider.com/Analyst+Comments/Biogen+%28BIIB%29+PT+Lowered+to+%24215+at+BofA+Securities/26791250.html Tue, 21 Jul 2026 05:31:45 -0400 BIIB http://www.streetinsider.com/Press+Releases/Synapticure+Launches+Groundbreaking+Ataxia+Care+Program%2C+Expanding+Access+to+Specialized+Neurology+Nationwide/26776767.html <div class="xn-content"> <p><b><i>Virtual-first, multidisciplinary care model delivers care for adults living with ataxias, connecting them to expert neurologist options nationwide. </i></b></p><p><span class="legendSpanClass"><location value="LU/us.il.chicgo" idsrc="xmltag.org" >CHICAGO</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- Synapticure, a leading virtual care company dedicated to improving access and outcomes for patients and caregivers living with neurodegenerative diseases, today announced the launch of a virtual ataxia care program. This program can help to provide timely access to specialized care for adults living with ataxias — a group of neurological conditions characterized by progressive loss of coordination, balance, and motor function. Synapticure partnered with <span value="NASDAQ-NMS:BIIB" idsrc="xmltag.org" >Biogen Inc.</span> (Nasdaq: http://www.streetinsider.com/Press+Releases/Synapticure+Launches+Groundbreaking+Ataxia+Care+Program%2C+Expanding+Access+to+Specialized+Neurology+Nationwide/26776767.html Thu, 16 Jul 2026 07:47:00 -0400 BIIB O.00070139 http://www.streetinsider.com/Press+Releases/Synapticure+Launches+Groundbreaking+Ataxia+Care+Program%2C+Expanding+Access+to+Specialized+Neurology+Nationwide/26776767.html <div class="xn-content"> <p><b><i>Virtual-first, multidisciplinary care model delivers care for adults living with ataxias, connecting them to expert neurologist options nationwide. </i></b></p><p><span class="legendSpanClass"><location value="LU/us.il.chicgo" idsrc="xmltag.org" >CHICAGO</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- Synapticure, a leading virtual care company dedicated to improving access and outcomes for patients and caregivers living with neurodegenerative diseases, today announced the launch of a virtual ataxia care program. This program can help to provide timely access to specialized care for adults living with ataxias — a group of neurological conditions characterized by progressive loss of coordination, balance, and motor function. Synapticure partnered with <span value="NASDAQ-NMS:BIIB" idsrc="xmltag.org" >Biogen Inc.</span> (Nasdaq: http://www.streetinsider.com/Press+Releases/Synapticure+Launches+Groundbreaking+Ataxia+Care+Program%2C+Expanding+Access+to+Specialized+Neurology+Nationwide/26776767.html Thu, 16 Jul 2026 07:47:00 -0400 BIIB O.00070139 http://www.streetinsider.com/PRNewswire/Synapticure+Launches+Groundbreaking+Ataxia+Care+Program%2C+Expanding+Access+to+Specialized+Neurology+Nationwide/26776767.html <div class="xn-content"> <p><b><i>Virtual-first, multidisciplinary care model delivers care for adults living with ataxias, connecting them to expert neurologist options nationwide. </i></b></p><p><span class="legendSpanClass"><location value="LU/us.il.chicgo" idsrc="xmltag.org" >CHICAGO</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- Synapticure, a leading virtual care company dedicated to improving access and outcomes for patients and caregivers living with neurodegenerative diseases, today announced the launch of a virtual ataxia care program. This program can help to provide timely access to specialized care for adults living with ataxias — a group of neurological conditions characterized by progressive loss of coordination, balance, and motor function. Synapticure partnered with <span value="NASDAQ-NMS:BIIB" idsrc="xmltag.org" >Biogen Inc.</span> (Nasdaq: http://www.streetinsider.com/PRNewswire/Synapticure+Launches+Groundbreaking+Ataxia+Care+Program%2C+Expanding+Access+to+Specialized+Neurology+Nationwide/26776767.html Thu, 16 Jul 2026 07:47:00 -0400 BIIB O.00070139 http://www.streetinsider.com/PRNewswire/Synapticure+Launches+Groundbreaking+Ataxia+Care+Program%2C+Expanding+Access+to+Specialized+Neurology+Nationwide/26776767.html <div class="xn-content"> <p><b><i>Virtual-first, multidisciplinary care model delivers care for adults living with ataxias, connecting them to expert neurologist options nationwide. </i></b></p><p><span class="legendSpanClass"><location value="LU/us.il.chicgo" idsrc="xmltag.org" >CHICAGO</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- Synapticure, a leading virtual care company dedicated to improving access and outcomes for patients and caregivers living with neurodegenerative diseases, today announced the launch of a virtual ataxia care program. This program can help to provide timely access to specialized care for adults living with ataxias — a group of neurological conditions characterized by progressive loss of coordination, balance, and motor function. Synapticure partnered with <span value="NASDAQ-NMS:BIIB" idsrc="xmltag.org" >Biogen Inc.</span> (Nasdaq: http://www.streetinsider.com/PRNewswire/Synapticure+Launches+Groundbreaking+Ataxia+Care+Program%2C+Expanding+Access+to+Specialized+Neurology+Nationwide/26776767.html Thu, 16 Jul 2026 07:47:00 -0400 BIIB O.00070139 http://www.streetinsider.com/FDA/FDA+approves+Leqembi+Iqlik+subcutaneous+injection+for+Alzheimer%27s/26773429.html <p>Eisai Co. and Biogen Inc. (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application for a once-weekly subcutaneous injection of lecanemab-irmb, marketed as Leqembi Iqlik, as an initiation dose for the treatment of early Alzheimer's disease.</p> <p>Leqembi Iqlik is administered via an autoinjector at 500 mg once weekly, delivered as two 250 mg injections, each taking approximately 15 seconds. The approval introduces an at-home administration option as an alternative to intravenous infusion from the start of treatment. After 18 months of either intravenous or subcutaneous treatment, patients may transition to a maintenance dose http://www.streetinsider.com/FDA/FDA+approves+Leqembi+Iqlik+subcutaneous+injection+for+Alzheimer%27s/26773429.html Wed, 15 Jul 2026 13:29:13 -0400 4523 A.06822034 A.50207248 BIIB ESAIY ESALF O.00386324 O.05105698 O.20026344 http://www.streetinsider.com/FDA/FDA+approves+Leqembi+Iqlik+subcutaneous+injection+for+Alzheimer%27s/26773429.html <p>Eisai Co. and Biogen Inc. (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application for a once-weekly subcutaneous injection of lecanemab-irmb, marketed as Leqembi Iqlik, as an initiation dose for the treatment of early Alzheimer's disease.</p> <p>Leqembi Iqlik is administered via an autoinjector at 500 mg once weekly, delivered as two 250 mg injections, each taking approximately 15 seconds. The approval introduces an at-home administration option as an alternative to intravenous infusion from the start of treatment. After 18 months of either intravenous or subcutaneous treatment, patients may transition to a maintenance dose http://www.streetinsider.com/FDA/FDA+approves+Leqembi+Iqlik+subcutaneous+injection+for+Alzheimer%27s/26773429.html Wed, 15 Jul 2026 13:29:13 -0400 4523 A.06822034 A.50207248 BIIB ESAIY ESALF O.00386324 O.05105698 O.20026344 http://www.streetinsider.com/FDA/FDA+approves+Leqembi+Iqlik+subcutaneous+injection+for+Alzheimer%27s/26773429.html <p>Eisai Co. and Biogen Inc. (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application for a once-weekly subcutaneous injection of lecanemab-irmb, marketed as Leqembi Iqlik, as an initiation dose for the treatment of early Alzheimer's disease.</p> <p>Leqembi Iqlik is administered via an autoinjector at 500 mg once weekly, delivered as two 250 mg injections, each taking approximately 15 seconds. The approval introduces an at-home administration option as an alternative to intravenous infusion from the start of treatment. After 18 months of either intravenous or subcutaneous treatment, patients may transition to a maintenance dose http://www.streetinsider.com/FDA/FDA+approves+Leqembi+Iqlik+subcutaneous+injection+for+Alzheimer%27s/26773429.html Wed, 15 Jul 2026 13:29:13 -0400 4523 A.06822034 A.50207248 BIIB ESAIY ESALF O.00386324 O.05105698 O.20026344 http://www.streetinsider.com/FDA/FDA+approves+Leqembi+Iqlik+subcutaneous+injection+for+Alzheimer%27s/26773429.html <p>Eisai Co. and Biogen Inc. (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application for a once-weekly subcutaneous injection of lecanemab-irmb, marketed as Leqembi Iqlik, as an initiation dose for the treatment of early Alzheimer's disease.</p> <p>Leqembi Iqlik is administered via an autoinjector at 500 mg once weekly, delivered as two 250 mg injections, each taking approximately 15 seconds. The approval introduces an at-home administration option as an alternative to intravenous infusion from the start of treatment. After 18 months of either intravenous or subcutaneous treatment, patients may transition to a maintenance dose http://www.streetinsider.com/FDA/FDA+approves+Leqembi+Iqlik+subcutaneous+injection+for+Alzheimer%27s/26773429.html Wed, 15 Jul 2026 13:29:13 -0400 4523 A.06822034 A.50207248 BIIB ESAIY ESALF O.00386324 O.05105698 O.20026344 http://www.streetinsider.com/FDA/FDA+approves+Leqembi+Iqlik+subcutaneous+injection+for+Alzheimer%27s/26773429.html <p>Eisai Co. and Biogen Inc. (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application for a once-weekly subcutaneous injection of lecanemab-irmb, marketed as Leqembi Iqlik, as an initiation dose for the treatment of early Alzheimer's disease.</p> <p>Leqembi Iqlik is administered via an autoinjector at 500 mg once weekly, delivered as two 250 mg injections, each taking approximately 15 seconds. The approval introduces an at-home administration option as an alternative to intravenous infusion from the start of treatment. After 18 months of either intravenous or subcutaneous treatment, patients may transition to a maintenance dose http://www.streetinsider.com/FDA/FDA+approves+Leqembi+Iqlik+subcutaneous+injection+for+Alzheimer%27s/26773429.html Wed, 15 Jul 2026 13:29:13 -0400 4523 A.06822034 A.50207248 BIIB ESAIY ESALF O.00386324 O.05105698 O.20026344 http://www.streetinsider.com/FDA/FDA+approves+Leqembi+Iqlik+subcutaneous+injection+for+Alzheimer%27s/26773429.html <p>Eisai Co. and Biogen Inc. (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application for a once-weekly subcutaneous injection of lecanemab-irmb, marketed as Leqembi Iqlik, as an initiation dose for the treatment of early Alzheimer's disease.</p> <p>Leqembi Iqlik is administered via an autoinjector at 500 mg once weekly, delivered as two 250 mg injections, each taking approximately 15 seconds. The approval introduces an at-home administration option as an alternative to intravenous infusion from the start of treatment. After 18 months of either intravenous or subcutaneous treatment, patients may transition to a maintenance dose http://www.streetinsider.com/FDA/FDA+approves+Leqembi+Iqlik+subcutaneous+injection+for+Alzheimer%27s/26773429.html Wed, 15 Jul 2026 13:29:13 -0400 4523 A.06822034 A.50207248 BIIB ESAIY ESALF O.00386324 O.05105698 O.20026344 http://www.streetinsider.com/FDA/FDA+approves+Leqembi+Iqlik+subcutaneous+injection+for+Alzheimer%27s/26773429.html <p>Eisai Co. and Biogen Inc. (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application for a once-weekly subcutaneous injection of lecanemab-irmb, marketed as Leqembi Iqlik, as an initiation dose for the treatment of early Alzheimer's disease.</p> <p>Leqembi Iqlik is administered via an autoinjector at 500 mg once weekly, delivered as two 250 mg injections, each taking approximately 15 seconds. The approval introduces an at-home administration option as an alternative to intravenous infusion from the start of treatment. After 18 months of either intravenous or subcutaneous treatment, patients may transition to a maintenance dose http://www.streetinsider.com/FDA/FDA+approves+Leqembi+Iqlik+subcutaneous+injection+for+Alzheimer%27s/26773429.html Wed, 15 Jul 2026 13:29:13 -0400 4523 A.06822034 A.50207248 BIIB ESAIY ESALF O.00386324 O.05105698 O.20026344 http://www.streetinsider.com/FDA/FDA+approves+Leqembi+Iqlik+subcutaneous+injection+for+Alzheimer%27s/26773429.html <p>Eisai Co. and Biogen Inc. (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application for a once-weekly subcutaneous injection of lecanemab-irmb, marketed as Leqembi Iqlik, as an initiation dose for the treatment of early Alzheimer's disease.</p> <p>Leqembi Iqlik is administered via an autoinjector at 500 mg once weekly, delivered as two 250 mg injections, each taking approximately 15 seconds. The approval introduces an at-home administration option as an alternative to intravenous infusion from the start of treatment. After 18 months of either intravenous or subcutaneous treatment, patients may transition to a maintenance dose http://www.streetinsider.com/FDA/FDA+approves+Leqembi+Iqlik+subcutaneous+injection+for+Alzheimer%27s/26773429.html Wed, 15 Jul 2026 13:29:13 -0400 4523 A.06822034 A.50207248 BIIB ESAIY ESALF O.00386324 O.05105698 O.20026344 http://www.streetinsider.com/FDA/FDA+approves+Leqembi+Iqlik+subcutaneous+injection+for+Alzheimer%27s/26773429.html <p>Eisai Co. and Biogen Inc. (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application for a once-weekly subcutaneous injection of lecanemab-irmb, marketed as Leqembi Iqlik, as an initiation dose for the treatment of early Alzheimer's disease.</p> <p>Leqembi Iqlik is administered via an autoinjector at 500 mg once weekly, delivered as two 250 mg injections, each taking approximately 15 seconds. The approval introduces an at-home administration option as an alternative to intravenous infusion from the start of treatment. After 18 months of either intravenous or subcutaneous treatment, patients may transition to a maintenance dose http://www.streetinsider.com/FDA/FDA+approves+Leqembi+Iqlik+subcutaneous+injection+for+Alzheimer%27s/26773429.html Wed, 15 Jul 2026 13:29:13 -0400 4523 A.06822034 A.50207248 BIIB ESAIY ESALF O.00386324 O.05105698 O.20026344 http://www.streetinsider.com/Management+Changes/Biogen+names+Michael+J.+Parini+as+chief+legal+officer/26771315.html <p>Biogen Inc. (NASDAQ: BIIB) announced the appointment of Michael J. Parini as Chief Legal Officer, effective August 3, 2026. Parini will join Biogen's Executive Committee and report to President and Chief Executive Officer Christopher A. Viehbacher, according to a press release from the Cambridge, Mass.-based company.</p> <p>In the role, Parini will oversee Biogen's global legal and compliance functions.</p> <p>Parini brings more than 20 years of senior legal and strategic leadership experience in the biopharmaceutical and biotechnology industry. He most recently served as Chief Executive Officer of Spur Therapeutics, where he led a scientific strategy shift and advanced a rare disease program from http://www.streetinsider.com/Management+Changes/Biogen+names+Michael+J.+Parini+as+chief+legal+officer/26771315.html Wed, 15 Jul 2026 08:15:12 -0400 BIIB http://www.streetinsider.com/Press+Releases/Biogen+Appoints+Michael+J.+Parini+as+Chief+Legal+Officer/26771305.html <p>CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hdPQ099W273Gim5FkV4hoZ2LxD0Bj9sqFdDq4UQFa1JfW7IOhfCGjxNr9gVDFtr19l6dbSofFGupx-15jWYzDw==" rel="nofollow" target="_blank">Biogen</a> Inc. (Nasdaq: BIIB) today announced the appointment of Michael J. Parini as Chief Legal Officer, effective August 3, 2026. Parini will serve as a member of Biogen's Executive Committee and report to Christopher A. Viehbacher, President and Chief Executive Officer. In this role, Mr. Parini will have responsibility for oversight of Biogen’s global legal and compliance functions.</p> <p>“Michael brings to Biogen a rare combination of deep legal and industry expertise as well as broad operational leadership that will further contribute to Biogen’s next chapter of http://www.streetinsider.com/Press+Releases/Biogen+Appoints+Michael+J.+Parini+as+Chief+Legal+Officer/26771305.html Wed, 15 Jul 2026 08:15:00 -0400 BIIB http://www.streetinsider.com/Globe+Newswire/Biogen+Appoints+Michael+J.+Parini+as+Chief+Legal+Officer/26771305.html <p>CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hdPQ099W273Gim5FkV4hoZ2LxD0Bj9sqFdDq4UQFa1JfW7IOhfCGjxNr9gVDFtr19l6dbSofFGupx-15jWYzDw==" rel="nofollow" target="_blank">Biogen</a> Inc. (Nasdaq: BIIB) today announced the appointment of Michael J. Parini as Chief Legal Officer, effective August 3, 2026. Parini will serve as a member of Biogen's Executive Committee and report to Christopher A. Viehbacher, President and Chief Executive Officer. In this role, Mr. Parini will have responsibility for oversight of Biogen’s global legal and compliance functions.</p> <p>“Michael brings to Biogen a rare combination of deep legal and industry expertise as well as broad operational leadership that will further contribute to Biogen’s next chapter of http://www.streetinsider.com/Globe+Newswire/Biogen+Appoints+Michael+J.+Parini+as+Chief+Legal+Officer/26771305.html Wed, 15 Jul 2026 08:15:00 -0400 BIIB http://www.streetinsider.com/Investing/Biogen+tumbles+8.7%25+as+breakthrough+Alzheimer%E2%80%99s+data+is+clouded+by+dosing+paradox/26766838.html <p data-path-to-node="3">Diranersen missed its primary endpoint: proving a dose-dependent response on the CDR-SB, a key measure of cognitive decline. Instead, the trial revealed a baffling "ceiling effect." The lowest dose delivered significant clinical benefits, while higher doses showed steeply diminishing returns.</p> <table data-path-to-node="4"> <thead> <tr> <td>Dose Regimen</td> <td>CDR-SB (Clinical Decline Slowing)</td> <td>ADAS-Cog13 (Cognitive Slowing)</td> <td>MMSE (Mental State Improvement)</td> </tr> </thead> <tbody> <tr> <td>60 mg (Every 6 Mos)</td> <td>26%</td> <td>42%</td> <td>50%</td> </tr> <tr> <td>115 mg (Every 6 Mos)</td> <td>14%</td> <td>32%</td> <td>34%</td> </tr> <tr> <td>115 mg (Every 3 Mos)</td> <td>9%</td> <td>29%</td> <td>38%</td> </tr> </tbody> </table> <p data-path-to-node="7">Diranersen is the first therapy to successfully demonstrate a massive 50% to 65% reduction in cerebrospinal fluid (CSF) total tau alongside significant reductions in brain tau pathology across <em data-path-to-node="7" data-index-in-node="218">all</em> doses. By targeting MAPT mRNA, it http://www.streetinsider.com/Investing/Biogen+tumbles+8.7%25+as+breakthrough+Alzheimer%E2%80%99s+data+is+clouded+by+dosing+paradox/26766838.html Tue, 14 Jul 2026 11:33:42 -0400 BIIB http://www.streetinsider.com/General+News/Biogen+tumbles+8.7%25+as+breakthrough+Alzheimer%E2%80%99s+data+is+clouded+by+dosing+paradox/26766838.html <p data-path-to-node="3">Diranersen missed its primary endpoint: proving a dose-dependent response on the CDR-SB, a key measure of cognitive decline. Instead, the trial revealed a baffling "ceiling effect." The lowest dose delivered significant clinical benefits, while higher doses showed steeply diminishing returns.</p> <table data-path-to-node="4"> <thead> <tr> <td>Dose Regimen</td> <td>CDR-SB (Clinical Decline Slowing)</td> <td>ADAS-Cog13 (Cognitive Slowing)</td> <td>MMSE (Mental State Improvement)</td> </tr> </thead> <tbody> <tr> <td>60 mg (Every 6 Mos)</td> <td>26%</td> <td>42%</td> <td>50%</td> </tr> <tr> <td>115 mg (Every 6 Mos)</td> <td>14%</td> <td>32%</td> <td>34%</td> </tr> <tr> <td>115 mg (Every 3 Mos)</td> <td>9%</td> <td>29%</td> <td>38%</td> </tr> </tbody> </table> <p data-path-to-node="7">Diranersen is the first therapy to successfully demonstrate a massive 50% to 65% reduction in cerebrospinal fluid (CSF) total tau alongside significant reductions in brain tau pathology across <em data-path-to-node="7" data-index-in-node="218">all</em> doses. By targeting MAPT mRNA, it http://www.streetinsider.com/General+News/Biogen+tumbles+8.7%25+as+breakthrough+Alzheimer%E2%80%99s+data+is+clouded+by+dosing+paradox/26766838.html Tue, 14 Jul 2026 11:33:42 -0400 BIIB http://www.streetinsider.com/Corporate+News/Real-world+Leqembi+study+shows+82%25+of+Alzheimer%27s+patients+stable/26766739.html <p>Eisai Co. and Biogen Inc. (NASDAQ: BIIB) released results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) Study showing that 82.5% of early Alzheimer's disease patients enrolled in the study remained stable or improved while receiving Leqembi over an average of 17 months of treatment.</p><p>The interim analysis, presented at the Alzheimer's Association International Conference in London on July 14, 2026, included 432 patients with early Alzheimer's disease who received at least seven Leqembi infusions as of May 2026. Among those patients, 75.9% remained in the same disease stage throughout treatment, while 6.6% improved, moving from mild Alzheimer's dementia to http://www.streetinsider.com/Corporate+News/Real-world+Leqembi+study+shows+82%25+of+Alzheimer%27s+patients+stable/26766739.html Tue, 14 Jul 2026 11:15:51 -0400 BIIB http://www.streetinsider.com/FDA/Real-world+Leqembi+study+shows+82%25+of+Alzheimer%27s+patients+stable/26766739.html <p>Eisai Co. and Biogen Inc. (NASDAQ: BIIB) released results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) Study showing that 82.5% of early Alzheimer's disease patients enrolled in the study remained stable or improved while receiving Leqembi over an average of 17 months of treatment.</p><p>The interim analysis, presented at the Alzheimer's Association International Conference in London on July 14, 2026, included 432 patients with early Alzheimer's disease who received at least seven Leqembi infusions as of May 2026. Among those patients, 75.9% remained in the same disease stage throughout treatment, while 6.6% improved, moving from mild Alzheimer's dementia to http://www.streetinsider.com/FDA/Real-world+Leqembi+study+shows+82%25+of+Alzheimer%27s+patients+stable/26766739.html Tue, 14 Jul 2026 11:15:51 -0400 BIIB http://www.streetinsider.com/Hot+Corp.+News/Real-world+Leqembi+study+shows+82%25+of+Alzheimer%27s+patients+stable/26766739.html <p>Eisai Co. and Biogen Inc. (NASDAQ: BIIB) released results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) Study showing that 82.5% of early Alzheimer's disease patients enrolled in the study remained stable or improved while receiving Leqembi over an average of 17 months of treatment.</p><p>The interim analysis, presented at the Alzheimer's Association International Conference in London on July 14, 2026, included 432 patients with early Alzheimer's disease who received at least seven Leqembi infusions as of May 2026. Among those patients, 75.9% remained in the same disease stage throughout treatment, while 6.6% improved, moving from mild Alzheimer's dementia to http://www.streetinsider.com/Hot+Corp.+News/Real-world+Leqembi+study+shows+82%25+of+Alzheimer%27s+patients+stable/26766739.html Tue, 14 Jul 2026 11:15:51 -0400 BIIB http://www.streetinsider.com/Hot+FDA+News/Real-world+Leqembi+study+shows+82%25+of+Alzheimer%27s+patients+stable/26766739.html <p>Eisai Co. and Biogen Inc. (NASDAQ: BIIB) released results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) Study showing that 82.5% of early Alzheimer's disease patients enrolled in the study remained stable or improved while receiving Leqembi over an average of 17 months of treatment.</p><p>The interim analysis, presented at the Alzheimer's Association International Conference in London on July 14, 2026, included 432 patients with early Alzheimer's disease who received at least seven Leqembi infusions as of May 2026. Among those patients, 75.9% remained in the same disease stage throughout treatment, while 6.6% improved, moving from mild Alzheimer's dementia to http://www.streetinsider.com/Hot+FDA+News/Real-world+Leqembi+study+shows+82%25+of+Alzheimer%27s+patients+stable/26766739.html Tue, 14 Jul 2026 11:15:51 -0400 BIIB